The Italian Competition Authority finds an agreement in the market for ophthalmic drugs used to treat vascular eyesight diseases to be anticompetitive (Roche / Novartis)

Italian Competition Authority imposes hefty fines on Roche and Novartis* On 27 February 2014, the Italian Competition Authority (“ICA”) issued a decision (in Italian only) finding that Roche and Novartis entered into an anticompetitive agreement in the market for ophthalmic drugs used to treat some serious vascular eyesight conditions, including age-related macular degeneration (“AMD”, which is the main cause of blindness in developed countries) in breach of article 101 of the Treaty on the Functioning of the European Union (“TFEU”) (see Newsletter 1/2013, p.

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteur

Citation

Gabriele Accardo, The Italian Competition Authority finds an agreement in the market for ophthalmic drugs used to treat vascular eyesight diseases to be anticompetitive (Roche / Novartis), 27 février 2014, e-Competitions February 2014, Art. N° 66857

Visites 247

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues